Coinbase Q1 2026 Earnings Miss Sends COIN Stock Lower Amid Crypto Market Slump 
Russian LNG Shadow Fleet Expands Amid Arctic LNG 2 Sanctions 
ECB Signals Possible Interest Rate Move if Inflation Outlook Fails to Improve 
Dell Stock Hits Record High After Trump Endorsement, AI Server Demand Fuels Rally 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
China Export Growth Surges in April as Global Buyers Rush to Secure Supplies 
Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
KOSPI Hits Record High as AI Chip Demand Boosts Samsung and SK Hynix 
Armani Group Eyes Strategic Stake Sale to Luxury Giants 
Malaysia Unveils Energy Security Plan Amid Iran Conflict and Rising Oil Costs 
TikTok Nears $400 Million Settlement With Trump Administration Over Child Privacy Lawsuit 
South Korea Central Bank Signals Inflation Concerns as Oil Prices Surge 
Oil Prices Surge Over 3% as Trump Rejects Iran Peace Response 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Norway Core Inflation Hits 3.2% in April, Fueling Interest Rate Hike Expectations 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Celltrion and Mirae Asset were said to have agreed on buying the largest stake in the UK-headquartered antibody-drug conjugates developer, Iksuda Therapeutics. Based on the report, the deal between the companies is worth $47 million.
The stake acquisition deal
As per The Korea Economic Daily, with its huge investment, Celltrion Inc. is expecting to expand its cancer drug line. The biopharmaceutical company headquartered in Incheon, South Korea, wants to develop more treatments in addition to its Truxima, a blood cancer drug, and Herzuma for breast cancer.
It was said that Iksuda has four ADC-based drugs that are already in pre-clinical development, including B-cell lymphomas. Celltrion can make use of these once the deal is fully completed.
ADC is an advanced technology that was created to specifically target a cancer cell. In any case, Celltrion and Mirae Asset have paid half of the investment price to the British biotech firm, and the rest of the payment will be delivered once agreed development milestones are reached.
"This stake investment will create synergy with our antibody treatments and add next-generation anticancer drugs to our pipeline," a Celltrion official said.
The benefits from the investments for Iksuda
Celltrion and Mirae Asset’s investment in Iksuda Therapeutics will make them the largest stakeholder in the UK-based company. The funding coming from the Korean firms will go to the development and advancement of Iksuda’s lead ADC assets and other technologies.
It was mentioned that Iksuda’s lead pre-clinical drug is called IKS03, and it is said to be a “best-in-class” CD19-targeted ADC candidate for B-cell cancers. Celltrion and Mirae’s multi-million investment will be used for IKSO3 to progress from its first human phase 1 clinical trial.
“This is a transformational investment milestone for Iksuda, enabling us to focus on the progression of our industry-leading ADC programs and bring them to the clinic, whilst supporting our commercial growth,” Iksuda Therapeutics CEO, Dr.Dave Simpson, said in a press release. “The funding not only reflects the potential of our technologies but also the unmatched expertise of the Iksuda team. We are grateful for the support of this group of investors and delighted to welcome them to the team.
